(firstQuint)SP2086 Pharmacokinetic Study in Renal Insufficiency Patients.

 This trial adopt in a parallel, open, single dose study design.

 The subject was divided into one of five groups according to the degree of renal Insufficiency, which including normal, mild, moderate, severe, and end-stage.

 All subjects were given SP2086 50mg, and collected the blood samples before and after the medicine taken.

.

 SP2086 Pharmacokinetic Study in Renal Insufficiency Patients@highlight

The purpose of the study is to investigate the SP2086 pharmacokinetic in Renal Insufficiency Patients.

